Compare VIR & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | MLKN |
|---|---|---|
| Founded | 2016 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 1994 |
| Metric | VIR | MLKN |
|---|---|---|
| Price | $8.40 | $15.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $19.63 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 669.8K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 4.99% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $68,556,000.00 | ★ $3,669,900,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $1,049.62 | $4.79 |
| P/E Ratio | ★ N/A | $23.52 |
| Revenue Growth | N/A | ★ 1.14 |
| 52 Week Low | $4.16 | $13.77 |
| 52 Week High | $10.91 | $23.18 |
| Indicator | VIR | MLKN |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 23.85 |
| Support Level | $5.14 | $13.77 |
| Resistance Level | $10.29 | $16.19 |
| Average True Range (ATR) | 0.47 | 0.61 |
| MACD | -0.18 | -0.32 |
| Stochastic Oscillator | 3.20 | 14.68 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.